|Title:||Comparisons of clinical outcomes in women with advanced ovarian cancer treated with frontline intraperitoneal versus dose-dense platinum/paclitaxel chemotherapy without bevacizumab||Authors:||Ting W.-H.
|Keywords:||Adjuvant; Chemotherapy; Cytoreduction; Ovarian neoplasms; Peritoneum||Issue Date:||2020||Publisher:||MDPI AG||Journal Volume:||17||Journal Issue:||10||Start page/Pages:||3603||Source:||International Journal of Environmental Research and Public Health||Abstract:||
Background: We aimed to compare the clinical outcomes between intraperitoneal chemotherapy and dose-dense chemotherapy for the frontline treatment of advanced ovarian, fallopian tube and primary peritoneal cancer in women not receiving bevacizumab. Methods: All consecutive women with stage II~IV cancer treated with either frontline intraperitoneal or dose-dense platinum/paclitaxel chemotherapy and not receiving bevacizumab between March 2006 and June 2019 were reviewed. Results: A total of 50 women (intraperitoneal group, n = 22; dose-dense group, n = 28) were reviewed. Median progression-free survival (32.6 months versus 14.2 months; adjusted hazard ratio = 0.38; 95% CI = 0.16 to 0.90, p = 0.03) and overall survival (not reached versus 30.7 months; adjusted hazard ratio = 0.23, 95% CI = 0.07 to 0.79, p = 0.02) were significantly higher in the intraperitoneal group than in the dose-dense group. A multivariable Cox proportional-hazards model also indicated that the number of frontline chemotherapy cycles (adjusted hazard ratio = 0.66, 95% CI 0.47 to 0.94, p = 0.02) was a predictor of better overall survival. Nausea/vomiting and nephrotoxicity occurred more frequently in the intraperitoneal group (p = 0.02 and <0.0001, respectively). Conclusions: Intraperitoneal chemotherapy seems to be superior in progression free survival and overall survival to dose-dense chemotherapy in the frontline treatment of women with optimally resected advanced ovarian, fallopian tube or primary peritoneal cancer and not receiving bevacizumab. ? 2020 by the authors. Licensee MDPI, Basel, Switzerland.
|ISSN:||1661-7827||DOI:||10.3390/ijerph17103603||SDG/Keyword:||bevacizumab; carboplatin; cisplatin; paclitaxel; antineoplastic agent; bevacizumab; carboplatin; paclitaxel; platinum; cancer; chemotherapy; comparative study; drug; multivariate analysis; survival; womens health; adult; advanced cancer; anemia; Article; cancer chemotherapy; cancer staging; cancer survival; clinical article; clinical outcome; comparative study; controlled study; diagnostic test accuracy study; diarrhea; dose densification; drug dosage form comparison; female; human; leukopenia; liver toxicity; middle aged; multiple cycle treatment; nausea; nephrotoxicity; neurotoxicity; ovary cancer; overall survival; peritoneum cancer; predictor variable; progression free survival; receiver operating characteristic; sensitivity and specificity; survival prediction; thrombocytopenia; uterine tube carcinoma; vomiting; young adult; disease free survival; ovary tumor; parenteral drug administration; uterine tube tumor; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Disease-Free Survival; Fallopian Tube Neoplasms; Female; Humans; Infusions, Parenteral; Middle Aged; Ovarian Neoplasms; Paclitaxel; Platinum
|Appears in Collections:||醫學系|
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.